Loading clinical trials...
Loading clinical trials...
The purpose of this study is to evaluate the efficacy and safety of repotrectinib and crizotinib in participants with locally advanced or metastatic TKI-naïve ROS1-positive non-small cell lung cancer ...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Bristol-Myers Squibb
Collaborators
NCT06380816 · Advanced Solid Tumours, Squamous Cell Carcinoma of Head and Neck, and more
NCT06855771 · Carcinoma, Non-Small-Cell Lung
NCT06758401 · Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, and more
NCT07222566 · Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, and more
NCT06120140 · Carcinoma, Non-Small-Cell Lung
Local Institution - 0221
Des Moines, Iowa
Local Institution - 0075
Boston, Massachusetts
Local Institution - 0201
Boston, Massachusetts
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions